Pembrolizumab + Cisplatin + Docetaxel + Carboplatin
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sinonasal Undifferentiated Carcinoma
Conditions
Sinonasal Undifferentiated Carcinoma
Trial Timeline
Dec 24, 2024 → Nov 1, 2026
NCT ID
NCT05925491About Pembrolizumab + Cisplatin + Docetaxel + Carboplatin
Pembrolizumab + Cisplatin + Docetaxel + Carboplatin is a phase 2 stage product being developed by Merck for Sinonasal Undifferentiated Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05925491. Target conditions include Sinonasal Undifferentiated Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05925491 | Phase 2 | Recruiting |